Calidi Biotherapeutics (CLDI) Capital Expenditures (2022 - 2025)
Calidi Biotherapeutics' quarterly Capital Expenditures came in at $29000.0 in Q4 2025, up 480.0% year-on-year from $5000.0 in Q4 2024, and up 7.41% quarter-over-quarter from $27000.0 in Q3 2025.
Calidi Biotherapeutics has reported Capital Expenditures for 4 years, with the latest figure at $29000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures rose 480.0% year-over-year to $29000.0; the trailing twelve-month figure through Dec 2025 stood at $120000.0 (up 650.0% YoY), and the FY2025 full-year result was $120000.0, up 650.0% from the prior year.
- Capital Expenditures for Q4 2025 stood at $29000.0, up from $27000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $489000.0 in Q3 2023, with the low at -$111000.0 in Q2 2023.
- Average Capital Expenditures over 4 years is $73500.0, with a median of $28000.0 recorded in 2025.
- Year-over-year, Capital Expenditures slumped 98.77% in 2024 and soared 480.0% in 2025.
- Tracing CLDI's Capital Expenditures over 4 years: stood at $161000.0 in 2022, then plunged by 56.52% to $70000.0 in 2023, then sank by 92.86% to $5000.0 in 2024, then soared by 480.0% to $29000.0 in 2025.
- The last three Capital Expenditures figures came in at $29000.0 (Q4 2025), $27000.0 (Q3 2025), and $57000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 230.60 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 29,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 489,000.00 |
| Sep 30, 2023 | 489,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Dec 31, 2022 | 161,000.00 |
| Dec 31, 2022 | 161,000.00 |